Therapeutic human papillomavirus vaccines: current clinical trials and future directions

Background: Cervical cancer is the second largest cause of cancer deaths in women worldwide. It is now evident that persistent infection with high-risk human papillomavirus (HPV) is necessary for the development and maintenance of cervical cancer. Thus, effective vaccination against HPV represents an opportunity to restrain cervical cancer and other important cancers. The FDA recently approved the HPV vaccine Gardasil for the preventive control of HPV, using HPV virus-like particles (VLP) to generate neutralizing antibodies against major capsid protein, L1. However, prophylactic HPV vaccines do not have therapeutic effects against pre-existing HPV infections and HPV-associated lesions. Furthermore, due to the considerable burden of HPV infections worldwide, it would take decades for preventive vaccines to affect the prevalence of cervical cancer. Thus, in order to speed up the control of cervical cancer and treat current infections, the continued development of therapeutic vaccines against HPV is critical. Therapeutic HPV vaccines can potentially eliminate pre-existing lesions and malignant tumors by generating cellular immunity against HPV-infected cells that express early viral proteins such as E6 and E7. Objective: This review discusses the future directions of therapeutic HPV vaccine approaches for the treatment of established HPV-associated malignancies, with emphasis on current progress of HPV vaccine clinical trials. Methods: Relevant literature is discussed. Results/conclusion: Though their development has been challenging, many therapeutic HPV vaccines have been shown to induce HPV-specific antitumor immune responses in preclinical animal models and several promising strategies have been applied in clinical trials. With continued progress in the field of vaccine development, HPV therapeutic vaccines may provide a potentially promising approach for the control of lethal HPV-associated malignancies.

[1]  Mimi Y. Kim,et al.  Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. , 2007, Gynecologic oncology.

[2]  J. Sin,et al.  Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Sjoerd H van der Burg,et al.  Design and development of synthetic peptide vaccines: past, present and future , 2007, Expert review of vaccines.

[4]  R. Roden,et al.  Opportunities to improve the prevention and treatment of cervical cancer. , 2007, Current molecular medicine.

[5]  D. Getnet,et al.  Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. , 2007, Blood.

[6]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[7]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[8]  T. Wu,et al.  DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  A. Chopra,et al.  Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. , 2007, Vaccine.

[10]  Shaw-Wei D Tsen,et al.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells , 2007, Expert review of vaccines.

[11]  D. Zelterman,et al.  Vesicular Stomatitis Virus-Based Therapeutic Vaccination Targeted to the E1, E2, E6, and E7 Proteins of Cottontail Rabbit Papillomavirus , 2007, Journal of Virology.

[12]  Tae Woo Kim,et al.  Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. , 2007, Cancer research.

[13]  J. Sin,et al.  Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines plus Cisplatin in an Animal Tumor Model: Causal Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy , 2007, Clinical Cancer Research.

[14]  C. Wheeler,et al.  Effi cacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind , randomised controlled trial , 2007 .

[15]  S. Hussain,et al.  Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. , 2007, Cancer immunity.

[16]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[17]  K. McMasters,et al.  Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice , 2007, Cancer Immunology, Immunotherapy.

[18]  A. Mackensen,et al.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.

[19]  D. Hoskin,et al.  Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. , 2006, Vaccine.

[20]  R. Rosales,et al.  Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine , 2006, Cancer Gene Therapy.

[21]  J. Palefsky,et al.  A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals , 2006, AIDS.

[22]  H. Kitchener,et al.  Prime‐boost vaccination strategy in women with high‐grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[23]  Chien-Fu Hung,et al.  A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. , 2006, Journal of biomedical science.

[24]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[25]  S. Quezada,et al.  Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. , 2006, Current opinion in immunology.

[26]  S. Bellone,et al.  HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. , 2006, Gynecologic oncology.

[27]  Qingzhen Zhao,et al.  Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Δ/mE7/TBhsp70Δ fusion protein vaccine in an animal model , 2006 .

[28]  S. H. van der Burg,et al.  Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. , 2005, Vaccine.

[29]  J. Sin,et al.  Both antigen optimization and lysosomal targeting are required for enhanced anti‐tumour protective immunity in a human papillomavirus E7‐expressing animal tumour model , 2005, Immunology.

[30]  Chien-Nan Lee,et al.  Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. , 2005, Cancer research.

[31]  S. Bellone,et al.  Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. , 2005, Current pharmaceutical design.

[32]  B. Dontje,et al.  Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice , 2005, Gene Therapy.

[33]  T. Wu,et al.  Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope , 2005, Gene Therapy.

[34]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[35]  S. Namkoong,et al.  Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. , 2005, Gynecologic oncology.

[36]  Tae Woo Kim,et al.  Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. , 2005, Human gene therapy.

[37]  Leaf Huang,et al.  Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer , 2005, Cancer Immunology, Immunotherapy.

[38]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[39]  Y. Qin,et al.  Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice. , 2005, Gynecologic oncology.

[40]  V. Azevedo,et al.  Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli , 2005, Journal of drug targeting.

[41]  J. Macková,et al.  Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. , 2005, Oncology reports.

[42]  D. Ladant,et al.  Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. , 2005, Cancer research.

[43]  J. Macková,et al.  Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara , 2005, Cancer Immunology, Immunotherapy.

[44]  Tae Woo Kim,et al.  Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. , 2005, Cancer research.

[45]  Y. Cheung,et al.  Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. , 2004, Vaccine.

[46]  V. Shahabi,et al.  Recombinant Listeria Vaccines Containing PEST Sequences Are Potent Immune Adjuvants for the Tumor-Associated Antigen Human Papillomavirus-16 E7 , 2004, Cancer Research.

[47]  I. Frazer,et al.  Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. , 2004, Vaccine.

[48]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[49]  V. Holan,et al.  Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells. , 2004, Oncology reports.

[50]  J. Macková,et al.  Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli β‐glucuronidase , 2004, The journal of gene medicine.

[51]  Tae Woo Kim,et al.  Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. , 2004, Vaccine.

[52]  I. Frazer,et al.  ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. , 2004, Vaccine.

[53]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[54]  H. Kitchener,et al.  Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). , 2004, Vaccine.

[55]  R. Rosales,et al.  Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. , 2004, Human gene therapy.

[56]  A. V. D. Van Der Zee,et al.  Superior Therapeutic Efficacy of Alphavirus-Mediated Immunization against Human Papilloma Virus Type 16 Antigens in a Murine Tumour Model: Effects of the Route of Immunization , 2004, Antiviral therapy.

[57]  J. Macková,et al.  Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. , 2004, International journal of oncology.

[58]  H. Deng,et al.  DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins , 2004, Cancer Gene Therapy.

[59]  T. Wu,et al.  Comparison of HPV DNA vaccines employing intracellular targeting strategies , 2004, Gene Therapy.

[60]  Tae Woo Kim,et al.  A DNA Vaccine Co-Expressing Antigen and an Anti-Apoptotic Molecule Further Enhances the Antigen-Specific CD8+ T-Cell Immune Response , 2004, Journal of Biomedical Science.

[61]  W. Ahn,et al.  CpG‐ODN‐stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen‐specific antitumour immunity in a HPV 16 E7‐associated animal tumour model , 2004, Immunology.

[62]  Y. Le Loir,et al.  An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. , 2004, Journal of medical microbiology.

[63]  S. H. van der Burg,et al.  Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination , 2004, Clinical Cancer Research.

[64]  Mariano J. Alvarez,et al.  Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. , 2004, Cancer cell.

[65]  A. Khromykh,et al.  Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour. , 2004, Virology.

[66]  J. Foidart,et al.  Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein–based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia , 2004, Cancer Immunology, Immunotherapy.

[67]  Francisco A. R. Garcia,et al.  ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2004, Obstetrics and gynecology.

[68]  T. Wu,et al.  Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death , 2004, Gene Therapy.

[69]  Y. Tsao,et al.  Cytotoxic-T-Lymphocyte Human Papillomavirus Type 16 E5 Peptide with CpG-Oligodeoxynucleotide Can Eliminate Tumor Growth in C57BL/6 Mice , 2004, Journal of Virology.

[70]  A. Deisseroth,et al.  Vaccination of Rabbits with an Adenovirus Vector Expressing the Papillomavirus E2 Protein Leads to Clearance of Papillomas and Infection , 2004, Journal of Virology.

[71]  Tae Woo Kim,et al.  Enhancement of DNA Vaccine Potency by Coadministration of a Tumor Antigen Gene and DNA Encoding Serine Protease Inhibitor-6 , 2004, Cancer Research.

[72]  J. Bubeník,et al.  Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. , 2004, International journal of oncology.

[73]  D. Munn,et al.  IDO and tolerance to tumors. , 2004, Trends in molecular medicine.

[74]  Alex C Rodriguez,et al.  Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. , 2004, Archives of otolaryngology--head & neck surgery.

[75]  S. H. van der Burg,et al.  Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  Tae Woo Kim,et al.  Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[77]  H. Kitchener,et al.  Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. , 2003, Cancer research.

[78]  Tae Woo Kim,et al.  Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life with Intracellular Targeting Strategies 1 , 2003, The Journal of Immunology.

[79]  D. Pardoll,et al.  Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. , 2003, Vaccine.

[80]  T. Wu,et al.  Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[81]  M. Pawlita,et al.  Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients , 2003, Journal of Cancer Research and Clinical Oncology.

[82]  Tae Woo Kim,et al.  Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. , 2003, The Journal of clinical investigation.

[83]  N. R. Chu.  Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease , 2003, Expert opinion on biological therapy.

[84]  T. Wu,et al.  Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. , 2003, Cancer research.

[85]  C. Crum,et al.  Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. , 2003, American journal of obstetrics and gynecology.

[86]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[87]  C. Hung,et al.  Improving DNA vaccine potency via modification of professional antigen presenting cells. , 2003, Current opinion in molecular therapeutics.

[88]  T. Wu,et al.  HPV DNA vaccines. , 2003, Frontiers in bioscience : a journal and virtual library.

[89]  H. Kitchener,et al.  Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[91]  S. H. van der Burg,et al.  Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. , 2002, Vaccine.

[92]  I. Frazer,et al.  Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. , 2002, Virology.

[93]  S. H. van der Burg,et al.  Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 , 2002, The Journal of Immunology.

[94]  G. Parham,et al.  Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. , 2002, The New England journal of medicine.

[95]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[96]  J. Palefsky,et al.  Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[97]  T. Wu,et al.  Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen , 2002, Journal of Virology.

[98]  T. Wu,et al.  Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. , 2002, Human gene therapy.

[99]  Y. Le Loir,et al.  Production of Human Papillomavirus Type 16 E7 Protein in Lactococcus lactis , 2002, Applied and Environmental Microbiology.

[100]  S. Isaacs,et al.  Regression of Established Human Papillomavirus Type 16 (HPV-16) Immortalized Tumors In Vivo by Vaccinia Viruses Expressing Different Forms of HPV-16 E7 Correlates with Enhanced CD8+ T-Cell Responses That Home to the Tumor Site , 2001, Journal of Virology.

[101]  R. Flavell,et al.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.

[102]  T. Wu,et al.  Improving Vaccine Potency Through Intercellular Spreading and Enhanced MHC Class I Presentation of Antigen1 , 2001, The Journal of Immunology.

[103]  T. Wu,et al.  Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. , 2001, Cancer research.

[104]  N. Christensen,et al.  Combination Treatment with Intralesional Cidofovir and Viral-DNA Vaccination Cures Large Cottontail Rabbit Papillomavirus-Induced Papillomas and Reduces Recurrences , 2001, Antimicrobial Agents and Chemotherapy.

[105]  T. Wu,et al.  Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Herpes Simplex Virus Type 1 VP22 Protein to Antigen , 2001, Journal of Virology.

[106]  T. Wu,et al.  Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen , 2001, Gene Therapy.

[107]  R. Roden,et al.  Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. , 2001, Human gene therapy.

[108]  T. Wu,et al.  Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. , 2001, Cancer research.

[109]  A. Fiander,et al.  Clinical studies of human papilloma vaccines in cervical cancer. , 2001, Advances in experimental medicine and biology.

[110]  D. Curiel,et al.  Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. , 2000, Cancer research.

[111]  D. Zelterman,et al.  Granulocyte-Macrophage Colony-Stimulating Factor Priming plus Papillomavirus E6 DNA Vaccination: Effects on Papilloma Formation and Regression in the Cottontail Rabbit Papillomavirus-Rabbit Model , 2000, Journal of Virology.

[112]  S. Wilczynski,et al.  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[113]  T. Wu,et al.  Immunotherapy of a human papillomavirus (HPV) type 16 E7‐expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette–Guérin (BCG) hsp65 and HPV16 E7 , 2000, Clinical and experimental immunology.

[114]  Tian-Li Wang,et al.  Antigen‐specific cancer immunotherapy using a GM‐CSF secreting allogeneic tumor cell‐based vaccine , 2000, International journal of cancer.

[115]  I. Shih,et al.  Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity , 2000, Gene Therapy.

[116]  P. Young,et al.  Stable High-Level Expression of Heterologous Genes In Vitro and In Vivo by Noncytopathic DNA-Based Kunjin Virus Replicon Vectors , 2000, Journal of Virology.

[117]  D. Pardoll,et al.  Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. , 2000, Vaccine.

[118]  Y. Tsao,et al.  Recombinant Adeno-Associated Virus Expressing Human Papillomavirus Type 16 E7 Peptide DNA Fused with Heat Shock Protein DNA as a Potential Vaccine for Cervical Cancer , 2000, Journal of Virology.

[119]  H. Grey,et al.  Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma , 2000, Journal of immunotherapy.

[120]  T. Wu,et al.  Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. , 2000, Cancer research.

[121]  R. Kurman,et al.  Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. , 1999, Human gene therapy.

[122]  Monahan Sj,et al.  Viral vectors for gene transfer into antigen presenting cells. , 1999 .

[123]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[124]  G. Fleuren,et al.  Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. , 1999, European journal of cancer.

[125]  J. Bubeník,et al.  Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. , 1999, International journal of oncology.

[126]  F. Holding,et al.  Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. , 1999, The Journal of infectious diseases.

[127]  A. Burny,et al.  Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. , 1999, International journal of cancer.

[128]  S. J. Monahan,et al.  Viral vectors for gene transfer into antigen presenting cells. , 1999, Current opinion in molecular therapeutics.

[129]  F. Holding,et al.  Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. , 1999, Vaccine.

[130]  F. Marincola,et al.  Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[131]  C.-H. Chen,et al.  Experimental vaccine strategies for cancer immunotherapy. , 1998, Journal of biomedical science.

[132]  P. Liljeström,et al.  Enhancing immune responses using suicidal DNA vaccines , 1998, Nature Biotechnology.

[133]  T. Banks,et al.  DNA Immunization against Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector , 1998, Journal of Virology.

[134]  R. Johnston,et al.  Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. , 1997, Virology.

[135]  P. Liljeström,et al.  Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. , 1997, AIDS research and human retroviruses.

[136]  R. Dummer,et al.  Interleukin‐10 is a growth factor for human melanoma cells and down‐regulates HLA class‐I, HLA class‐II and ICAM‐1 molecules , 1997, International journal of cancer.

[137]  S. Stacey,et al.  A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer , 1996, The Lancet.

[138]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[139]  Kathleen R. Cho,et al.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[140]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[141]  V. Moreno,et al.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.